|
1
|
Foster R, Buckanovich RJ and Rueda BR:
Ovarian cancer stem cells: Working towards the root of stemness.
Cancer Lett. 338:147–157. 2013. View Article : Google Scholar
|
|
2
|
Razi S, Ghoncheh M, Mohammadian-Hafshejani
A, Aziznejhad H, Mohammadian M and Salehiniya H: The incidence and
mortality of ovarian cancer and their relationship with the Human
Development Index in Asia. Ecancermedicalscience. 10:6282016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mitra T, Prasad P, Mukherjee P, Chaudhuri
SR, Chatterji U and Roy SS: Stemness and chemoresistance are
imparted to the OC cells through TGFβ1 driven EMT. J Cell Biochem.
119:5775–5787. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Manchanda R and Menon U: Setting the
threshold for surgical prevention in women at increased risk of
ovarian cancer. Int J Gynecol Cancer. 28:34–42. 2018. View Article : Google Scholar
|
|
5
|
Di Donato V, Kontopantelis E, Aletti G,
Casorelli A, Piacenti I, Bogani G, Lecce F and Benedetti Panici P:
Trends in mortality after primary cytoreductive surgery for ovarian
cancer: A systematic review and metaregression of randomized
clinical trials and observational studies. Ann Surg Oncol.
24:1688–1697. 2017. View Article : Google Scholar
|
|
6
|
Abu Hassaan SO: Monitoring ovarian cancer
patients during chemotherapy and follow-up with the serum tumor
marker CA125. Dan Med J. 65:2018.PubMed/NCBI
|
|
7
|
Xu W, He H, Zheng L, Xu JW, Lei CZ, Zhang
GM, Dang RH, Niu H, Qi XL, Chen H and Huang YZ: Detection of 19-bp
deletion within PLAG1 gene and its effect on growth traits in
cattle. Gene. 675:144–149. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
https://www.genecards.org/cgi-bin/carddisp.pl?gene=PLAG1
|
|
9
|
de Brito BS, Giovanelli N, Egal ES,
Sanchez-Romero C, Nascimento JS, Martins AS, Tincani AJ, Del Negro
A, Gondak RO, Almeida OP, et al: Loss of expression of Plag1 in
malignant transformation from pleomorphic adenoma to carcinoma ex
pleomorphic adenoma. Hum Pathol. 57:152–159. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Andreasen S, von Holstein SL, Homøe P and
Heegaard S: Recurrent rearrangements of the PLAG1 and HMGA2 genes
in lacrimal gland pleomorphic adenoma and carcinoma ex pleo-morphic
adenoma. Acta Ophthalmol. 96:e768–e771. 2018. View Article : Google Scholar
|
|
11
|
Matsuyama A, Hisaoka M and Hashimoto H:
PLAG1 expression in mesenchymal tumors: An immunohistochemical
study with special emphasis on the pathogenetical distinction
between soft tissue myoepithelioma and pleomorphic adenoma of the
salivary gland. Pathol Int. 62:1–7. 2012. View Article : Google Scholar
|
|
12
|
Hu ZY, Yuan SX, Yang Y, Zhou WP and Jiang
H: Pleomorphic adenoma gene 1 mediates the role of karyopherin
alpha 2 and has prognostic significance in hepatocellular
carcinoma. J Exp Clin Cancer Res. 33:612014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sun YP, Lu F, Han XY, Ji M, Zhou Y, Zhang
AM, Wang HC, Ma DX and Ji CY: MiR-424 and miR-27a increase TRAIL
sensitivity of acute myeloid leukemia by targeting PLAG1.
Oncotarget. 7:25276–25290. 2016.PubMed/NCBI
|
|
14
|
Xu L, Yin S, Banerjee S, Sarkar F and
Reddy KB: Enhanced anticancer effect of the combination of
cisplatin and TRAIL in triple-negative breast tumor cells. Mol
Cancer Ther. 10:550–557. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Gasparian ME, Bychkov ML, Yagolovich AV,
Kirpichnikov MP and Dolgikh DA: The effect of cisplatin on
cytotoxicity of anticancer cytokine TRAIL and its
receptor-selective mutant variant DR5-B1. Dokl Biochem
Biophys. 477:385–388. 2017. View Article : Google Scholar
|
|
16
|
Qian B, Katsaros D, Lu L, Canuto EM,
Benedetto C, Beeghly-Fadiel A and Yu H: IGF-II promoter specific
methylation and expression in epithelial ovarian cancer and their
associations with disease characteristics. Oncol Rep. 25:203–213.
2011.
|
|
17
|
Zhuang M, Shi Q, Zhang X, Ding Y, Shan L,
Shan X, Qian J, Zhou X, Huang Z, Zhu W, et al: Involvement of
miR-143 in cisplatin resistance of gastric cancer cells via
targeting IGF1R and BCL2. Tumour Biol. 36:2737–2745. 2015.
View Article : Google Scholar
|
|
18
|
Knowlden JM, Gee JM, Barrow D, Robertson
JF, Ellis IO, Nicholson RI and Hutcheson IR: erbB3 recruitment of
insulin receptor substrate 1 modulates insulin-like growth factor
receptor signalling in oestrogen receptor-positive breast cancer
cell lines. Breast Cancer Res. 13:R932011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Ding YC, McGuffog L, Healey S, Friedman E,
Laitman Y, Paluch-Shimon S, Kaufman B; SWE-BRCA; Liljegren A,
Lindblom A, et al: A nonsynonymous polymorphism in IRS1 modifies
risk of developing breast and ovarian cancers in BRCA1 and ovarian
cancer in BRCA2 mutation carriers. Cancer Epidemiol Biomarkers
Prev. 21:1362–1370. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yang M, Shan X, Zhou X, Qiu T, Zhu W, Ding
Y, Shu Y and Liu P: miR-1271 regulates cisplatin resistance of
human gastric cancer cell lines by targeting IGF1R, IRS1, mTOR, and
BCL2. Anticancer Agents Med Chem. 14:884–891. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Bardou P, Mariette J, Escudié F, Djemiel C
and Klopp C: Jvenn: An interactive Venn diagram viewer. BMC
Bioinformatics. 15:2932014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Piñero J, Bravo À, Queralt-Rosinach N,
Gutiérrez-Sacristán A, Deu-Pons J, Centeno E, García-García J, Sanz
F and Furlong LI: DisGeNET: A comprehensive platform integrating
information on human disease-associated genes and variants. Nucleic
Acids Res. 45:D833–D839. 2017. View Article : Google Scholar :
|
|
23
|
Szklarczyk D, Franceschini A, Wyder S,
Forslund K, Heller D, Huerta-Cepas J, Simonovic M, Roth A, Santos
A, Tsafou KP, et al: STRING v10: Protein-protein interaction
networks, integrated over the tree of life. Nucleic Acids Res.
43:D447–D452. 2015. View Article : Google Scholar
|
|
24
|
Shannon P, Markiel A, Ozier O, Baliga NS,
Wang JT, Ramage D, Amin N, Schwikowski B and Ideker T: Cytoscape: A
software environment for integrated models of biomolecular
interaction networks. Genome Res. 13:2498–2504. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Chang SJ, Bristow RE and Ryu HS: Analysis
of paraaortic lymphadenectomy up to the level of the renal vessels
in apparent early-stage ovarian cancer. J Gynecol Oncol. 24:29–36.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tuo YL, Li XM and Luo J: Long noncoding
RNA UCA1 modulates breast cancer cell growth and apoptosis through
decreasing tumor suppressive miR-143. Eur Rev Med Pharmacol Sci.
19:3403–3411. 2015.PubMed/NCBI
|
|
27
|
Tayama S, Motohara T, Narantuya D, Li C,
Fujimoto K, Sakaguchi I, Tashiro H, Saya H, Nagano O and Katabuchi
H: The impact of EpCAM expression on response to chemotherapy and
clinical outcomes in patients with epithelial ovarian cancer.
Oncotarget. 8:44312–44325. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zheng J, Zhao S, Yu X, Huang S and Liu HY:
Simultaneous targeting of CD44 and EpCAM with a bispecific aptamer
effectively inhibits intraperitoneal ovarian cancer growth.
Theranostics. 7:1373–1388. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Quinn MC, Filali-Mouhim A, Provencher DM,
Mes-Masson AM and Tonin PN: Reprogramming of the transcriptome in a
novel chromosome 3 transfer tumor suppressor ovarian cancer cell
line model affected molecular networks that are characteristic of
ovarian cancer. Mol Carcinog. 48:648–661. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Shigemasa K, Hu C, West CM, Clarke J,
Parham GP, Parmley TH, Korourian S, Baker VV and O'Brien TJ: p16
overexpression: A potential early indicator of transformation in
ovarian carcinoma. J Soc Gynecol Investig. 4:95–102.
1997.PubMed/NCBI
|
|
31
|
Toyama A, Suzuki A, Shimada T, Aoki C,
Aoki Y, Umino Y, Nakamura Y, Aoki D and Sato TA: Proteomic
characterization of ovarian cancers identifying annexin-A4,
phosphoserine amino-transferase, cellular retinoic acid-binding
protein 2, and serpin B5 as histology-specific biomarkers. Cancer
Sci. 103:747–755. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Cho H, Kang ES, Hong SW, Oh YJ, Choi SM,
Kim SW, Kim SH, Kim YT, Lee KS, Choi YK and Kim JH: Genomic and
proteomic characterization of YDOV-157, a newly established human
epithelial ovarian cancer cell line. Mol Cell Biochem. 319:189–201.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Dong Y, Li J, Han F, Chen H, Zhao X, Qin
Q, Shi R and Liu J: High IGF2 expression is associated with poor
clinical outcome in human ovarian cancer. Oncol Rep. 34:936–942.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Liefers-Visser JAL, Meijering RAM, Reyners
AKL, van der Zee AGJ and de Jong S: IGF system targeted therapy:
Therapeutic opportunities for ovarian cancer. Cancer Treat Rev.
60:90–99. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Abi Habib W, Brioude F, Edouard T, Bennett
JT, Lienhardt-Roussie A, Tixier F, Salem J, Yuen T, Azzi S, Le Bouc
Y, et al: Genetic disruption of the oncogenic HMGA2-PLAG1-IGF2
pathway causes fetal growth restriction. Genet Med. 20:250–258.
2018. View Article : Google Scholar
|
|
36
|
Zou Y, Wang F, Liu FY, Huang MZ, Li W,
Yuan XQ, Huang OP and He M: RNF43 mutations are recurrent in
Chinese patients with mucinous ovarian carcinoma but absent in
other subtypes of ovarian cancer. Gene. 531:112–116. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Abramov Y, Carmi S, Anteby SO and Ringel
I: Characterization of ovarian cancer cell metabolism and response
to chemotherapy by (31)p magnetic resonance spectroscopy. Oncol
Res. 20:529–536. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Karki R, Seagle BL, Nieves-Neira W and
Shahabi S: Taxanes in combination with biologic agents for ovarian
and breast cancers. Anticancer Drugs. 25:536–554. 2014. View Article : Google Scholar
|
|
39
|
Wang W, Ren F, Wu Q, Jiang D, Li H, Peng
Z, Wang J and Shi H: MicroRNA-497 inhibition of ovarian cancer cell
migration and invasion through targeting of SMAD specific E3
ubiquitin protein ligase 1. Biochem Biophys Res Commun.
449:432–437. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Li C, Ding H, Tian J, Wu L, Wang Y, Xing Y
and Chen M: Forkhead box protein C2 (FOXC2) promotes the resistance
of human ovarian cancer cells to cisplatin in vitro and in vivo.
Cell Physiol Biochem. 39:242–252. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Jin L, Chun J, Pan C, Kumar A, Zhang G, Ha
Y, Li D, Alesi GN, Kang Y, Zhou L, et al: The PLAG1-GDH1 axis
promotes anoikis resistance and tumor metastasis through
CamKK2-AMPK signaling in LKB1-deficient lung cancer. Mol Cell.
69:87.e7–99.e7. 2018. View Article : Google Scholar
|
|
42
|
Pallasch CP, Patz M, Park YJ, Hagist S,
Eggle D, Claus R, Debey-Pascher S, Schulz A, Frenzel LP, Claasen J,
et al: miRNA deregulation by epigenetic silencing disrupts
suppression of the oncogene PLAG1 in chronic lymphocytic leukemia.
Blood. 114:3255–3264. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Van Dyck F, Scroyen I, Declercq J, Sciot
R, Kahn B, Lijnen R and Van de Ven WJ: aP2-Cre-mediated expression
activation of an oncogenic PLAG1 transgene results in cavernous
angiomatosis in mice. Int J Oncol. 32:33–40. 2008.
|
|
44
|
Declercq J, Van Dyck F, Braem CV, Van
Valckenborgh IC, Voz M, Wassef M, Schoonjans L, Van Damme B, Fiette
L and Van de Ven WJ: Salivary gland tumors in transgenic mice with
targeted PLAG1 proto-oncogene overexpression. Cancer Res.
65:4544–4553. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Arima T and Wake N: Establishment of the
primary imprint of the HYMAI/PLAGL1 imprint control region during
oogenesis. Cytogenet Genome Res. 113:247–252. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Sekiya R, Maeda M, Yuan H, Asano E, Hyodo
T, Hasegawa H, Ito S, Shibata K, Hamaguchi M, Kikkawa F, et al:
PLAGL2 regulates actin cytoskeletal architecture and cell
migration. Carcinogenesis. 35:1993–2001. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Van Dyck F, Declercq J, Braem CV and Van
de Ven WJ: PLAG1, the prototype of the PLAG gene family:
Versatility in tumour development (Review). Int J Oncol.
30:765–774. 2007.PubMed/NCBI
|
|
48
|
Xu B, Zhang X, Wang S and Shi B: MiR-449a
suppresses cell migration and invasion by targeting PLAGL2 in
breast cancer. Pathol Res Pract. 214:790–795. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Zhu J, Declercq J, Willekens K, Creemers
J, Vermorken AJM and de Ven WJV: Abstract 1981: Interference of the
polyphenolic compound curcumin with expression regulation of target
genes of the PLAG1 oncogenic transcription factor. Cancer Res.
72:19812012.
|
|
50
|
Akhtar M, Holmgren C, Göndör A, Vesterlund
M, Kanduri C, Larsson C and Ekström TJ: Cell type and
context-specific function of PLAG1 for IGF2 P3 promoter activity.
Int J Oncol. 41:1959–1966. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wang Y, Shang W, Lei X, Shen S, Zhang H,
Wang Z, Huang L, Yu Z, Ong H, Yin X, et al: Opposing functions of
PLAG1 in pleomorphic adenoma: A microarray analysis of PLAG1
transgenic mice. Biotechnol Lett. 35:1377–1385. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Lu L, Katsaros D, de la Longrais IA,
Sochirca O and Yu H: Hypermethylation of let-7a-3 in epithelial
ovarian cancer is associated with low insulin-like growth factor-II
expression and favorable prognosis. Cancer Res. 67:10117–10122.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Lu L, Katsaros D, Wiley A, Rigault de la
Longrais IA, Puopolo M, Schwartz P and Yu H: Promoter-specific
transcription of insulin-like growth factor-II in epithelial
ovarian cancer. Gynecol Oncol. 103:990–995. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Eckstein N, Servan K, Hildebrandt B,
Pölitz A, von Jonquières G, Wolf-Kümmeth S, Napierski I, Hamacher
A, Kassack MU, Budczies J, et al: Hyperactivation of the
insulin-like growth factor receptor I signaling pathway is an
essential event for cisplatin resistance of ovarian cancer cells.
Cancer Res. 69:2996–3003. 2009. View Article : Google Scholar : PubMed/NCBI
|
